Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 1
2014 5
2015 2
2016 1
2017 5
2018 8
2019 7
2020 6
2021 4
2022 6
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Cortés J, et al. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. N Engl J Med. 2022. PMID: 35320644 Clinical Trial.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators. Modi S, et al. N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11. N Engl J Med. 2020. PMID: 31825192 Free PMC article. Clinical Trial.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Martin M, et al. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. Lancet Oncol. 2017. PMID: 29146401 Clinical Trial.
Immune-mediated diseases involving central and peripheral nervous systems.
Leboyan A, Esselin F, Bascou AL, Duflos C, Ion I, Charif M, Castelnovo G, Carra-Dalliere C, Ayrignac X, Kerschen P, Chbicheb M, Nguyen L, Maria ATJ, Guilpain P, Carriere M, de Champfleur NM, Vincent T, Jentzer A, Labauge P, Devaux JJ, Taieb G. Leboyan A, et al. Among authors: charif m. Eur J Neurol. 2023 Feb;30(2):490-500. doi: 10.1111/ene.15628. Epub 2022 Nov 27. Eur J Neurol. 2023. PMID: 36366904
Reversible giant arachnoid granulations.
Taieb G, Dargazanli C, Prin P, Charif M, Ducros A. Taieb G, et al. Among authors: charif m. Neurology. 2018 Dec 11;91(24):1107-1108. doi: 10.1212/WNL.0000000000006656. Neurology. 2018. PMID: 30530555 No abstract available.
MRI volumetric morphometry in vascular parkinsonism.
Dunet V, Deverdun J, Charroud C, Le Bars E, Molino F, Menjot de Champfleur S, Maury F, Charif M, Ayrignac X, Labauge P, Castelnovo G, Pinna F, Bonafe A, Geny C, Menjot de Champfleur N. Dunet V, et al. Among authors: charif m. J Neurol. 2017 Jul;264(7):1511-1519. doi: 10.1007/s00415-017-8561-5. Epub 2017 Jul 1. J Neurol. 2017. PMID: 28669119
A Clinico-Radiological Study of Cerebral Amyloid Angiopathy-Related Inflammation.
Coulette S, Renard D, Lehmann S, Raposo N, Arquizan C, Charif M, Thouvenot E, Wacongne A, Viguier A, Bonneville F, Allou T, Boukriche Y, Chiper L, Blanchet Fourcade G, Gabelle A, Ducros A, Duflos C, Labauge P, Menjot de Champfleur N, Ayrignac X. Coulette S, et al. Among authors: charif m. Cerebrovasc Dis. 2019;48(1-2):38-44. doi: 10.1159/000502832. Epub 2019 Sep 24. Cerebrovasc Dis. 2019. PMID: 31550722
CSF β-amyloid is not a prognostic marker in multiple sclerosis patients.
Petitfour J, Ayrignac X, Ginestet N, Prin P, Carra-Dallière C, Hirtz C, Charif M, Lehmann S, Labauge P. Petitfour J, et al. Among authors: charif m. Mult Scler Relat Disord. 2022 Dec;68:104096. doi: 10.1016/j.msard.2022.104096. Epub 2022 Aug 8. Mult Scler Relat Disord. 2022. PMID: 36037751
42 results